Special Issue

Bone Cancer: From Molecular Mechanism to Treatment

Message from the Guest Editors

In recent years, significant advancements have been made in the medical field for the treatment of bone cancer. High-dose chemotherapy has improved treatment outcomes, and the application of magnetic resonance imaging (MRI) and computed tomography (CT) scans has clearly shown the specific location. extent, and degree of invasion of bone cancer. These advancements have facilitated the complete surgical removal of bone cancer, thereby significantly increasing the success rate of limb salvage surgeries and reducing the need for amputation in a small fraction of patients with bone cancer. Consequently, the five-year survival rate for primary bone cancer can reach 70% or higher when detected and treated early. Nonetheless, if the cancer is at an advanced stage or has metastasized, the five-year survival rate can drop to below 30%. Conventional chemotherapeutic agents tend to be ineffective against metastatic bone cancer due to its heightened malignancy and propensity for invasion. Therefore, there is a pressing need to identify new pretreatment prognostic markers and develop new targeted drugs as adjuvants for chemotherapy.

Guest Editors

Dr. Chih-Yang Lin

Translational Medicine Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan

Dr. Syuan-Ling Lin

Translational Medicine Research Center, China Medical University Hospital, Taichung City 404327, Taiwan

Deadline for manuscript submissions

29 August 2025



Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



mdpi.com/si/209525

Life
Editorial Office
MDPI, Grosspeteranlage 9
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/ life





Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)

